Tag: ESC 2017
Use of apixaban prior to cardioversion reduces risk of stroke
According to the results of the EMANATE trial, patients with atrial fibrillation (AF) who receive apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) before undergoing elective cardioversion of...
Catheter ablation lowers mortality in atrial fibrillation patients with heart failure
Catheter ablation of atrial fibrillation significantly reduces mortality and hospitalisation in atrial fibrillation patients with heart failure in comparison with conventional treatment, data from...
Left atrial appendage closure during heart surgery protects the brain from...
Closure of the left atrial appendage during open heart surgery protects the brain from infarctions and stroke, and could be routinely performed in the future,...
ESC 2017: New research confirms significance of AliveCor’s 30-second ECG
AliveCor, the leader in FDA-cleared personal ECG technology, have announced the results of four clinical research presentations that demonstrate that AliveCor's hyper-fast, 30 second,...
ESC 2017: New subanalysis highlights benefits of edoxaban over warfarin in...
New subanalysis data demonstrate edoxaban (Lixana, Daiichi Sankyo) provide comparable efficacy and greater safety compared to warfarin, across non-valvular atrial fibrillation patients with different...
ESC 2017: Atrial fibrillation associated with a high financial, economic, and...
The first health economics data from GARFIELD-AF (Global anticoagulant registry in the field–atrial fibrillation) was presented at the European Society of Cardiology (ESC) congress...
ESC 2017: Rivaroxaban significantly lowers risk of stroke, cardiovascular death, and...
The COMPASS study, which was presented at the European Society of Cardiology (ESC) congress (26–30 August, Barcelona, Spain), has shown that rivaroxaban (Xarelto, Bayer)...
ESC 2017: EHRA and Biotronik mark 10 years of collaboration with...
At the European Society of Cardiology (ESC) congress (26–30 August, Barcelona, Spain), the European Heart Rhythm Association (EHRA) released an analytical supplement to the...
ESC 2017: Apixaban lowers risk of stroke in atrial fibrillation patients...
Data from the EMANATE trial, which was presented at a Hot Line session of the European Society of Cardiology (ESC) congress (26–30 August, Barcelona,...
ESC 2017: Case builds for dropping aspirin from triple therapy in...
The RE-DUAL PCI trial indicates that dual therapy with the non-vitamin K antagonist oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim)—and not aspirin—and a P2Y12 inhibitor...